LINC00861 was identified as a potential immunotherapy intervention target in patients with prostate cancer and was significantly correlated with CTLA4, which is consistent with the findings of our correlation study between prognosis-related lncRNAs and immunological checkpoints (Hu et al., 2021). This evidence concerns the gene CTLA4 and prostate carcinoma.